Skip to main content

Fosun Pharma Acquires Rights to Next-Gen Botox-type Drug in $260 Million Deal

Shanghai Fosun Pharma in-licensed rights to a Revance (NSDQ: RVNC) neuromodulator for aesthetic and therapeutic use in an agreement potentially worth $260 million. Fosun will pay $30 million upfront and up to $230 million in milestones, plus royalties. The first neuromodulator with long-acting duration, DaxibotulinumtoxinA (RT002) is also the first Botox-type product formulated without human blood-derived products or manufactured using animal-derived proteins. More details.... Stock Symbol: (SHA: 600196; HK: 02196) Share this with colleagues: // //
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.